[1] |
Turkalp Z,Karamchandani J,Das S. IDH mutation in glioma: new insights and promises for the future[J]. JAMA Neurol, 2014, 71(10): 1319-1325.
|
[2] |
Eckel-Passow JE,Lachance DH,Molinaro AM, et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors[J]. N Engl J Med, 2015, 372(26): 2499-508.
|
[3] |
Pesenti C,Paganini L,Fontana L, et al. Mass spectrometry-based assay for the molecular diagnosis of glioma: concomitant detection of chromosome 1p/19q codeletion, and IDH1, IDH2, and TERT mutation status[J]. Oncotarget, 2017, 8(34): 57134-57148.
|
[4] |
Mu L,Xu W,Li Q, et al. IDH1 R132H mutation is accompanied with malignant progression of paired primary-recurrent astrocytic tumours[J]. J Cancer, 2017, 8(14): 2704-2712.
|
[5] |
Zhao S,Lin Y,Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha[J]. Science, 2009, 324(5924): 261-265.
|
[6] |
Yalaza C,Ak H,Cagli MS, et al. R132H Mutation in IDH1 Gene is associated with increased tumor HIF1-alpha and serum VEGF levels in primary glioblastoma multiforme[J]. Ann Clin Lab Sci, 2017, 47(3): 362-364.
|
[7] |
Yan H,Parsons DW,Jin G, et al. IDH1 and IDH2 mutations in gliomas[J]. N Engl J Med, 2009, 360(8): 765-773.
|
[8] |
Turcan S,Rohle D,Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype[J]. Nature, 2012, 483(7390): 479-483.
|
[9] |
Dimitrov L,Hong CS,Yang C, et al. New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma[J]. Int J Med Sci, 2015, 12(3): 201-213.
|
[10] |
王国良,赛克,公方和,等.异柠檬酸脱氢酶1基因突变增加胶质瘤细胞对替莫唑胺的敏感性[J].中国临床神经外科杂志, 2014, 19(2): 95-98.
|
[11] |
Chen N,Yu T,Gong J, et al. IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients[J]. Pathology, 2016, 48(7): 675-683.
|
[12] |
Lopci E,Riva M,Olivari L, et al. Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma[J]. Eur J Nucl Med Mol Imaging, 2017, 44(7): 1155-1164.
|
[13] |
Opoku-Darko M,Lang ST,Artindale J, et al. Surgical management of incidentally discovered diffusely infiltrating low-grade glioma[J]. J Neurosurg, 2017, Epub ahead of print.
|
[14] |
Gessler F,Zappi J,Konczalla J, et al. Secondary glioblastoma: molecular and clinical factors that affect outcome after malignant progression of a lower grade tumor[J]. World Neurosurg, 2017, 102: 49-55.
|
[15] |
Yang Y,Mao Q,Wang X, et al. An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy[J]. J Clin Neurosci, 2016, 31: 56-62.
|